OOO " Jodas Expoim"

OOO "Jodas Expoim" is a pharmaceutical importer based in Russia, specializing in the procurement of finished pharmaceutical formulations from India. Established in 2006, Jodas Expoim has developed a significant presence in the Russian pharmaceutical market, focusing on the importation of oncology and critical care medications. The company operates as a primary wholesaler, sourcing a diverse range of pharmaceutical products to meet the therapeutic needs of the Russian healthcare system.

Headquartered in Russia, OOO "Jodas Expoim" collaborates closely with its Indian counterpart, Jodas Expoim Private Limited, which is based in Hyderabad, Telangana, India. This partnership facilitates the efficient importation and distribution of high-quality pharmaceutical formulations, ensuring a steady supply of essential medications to the Russian market. The company's strategic focus on oncology and critical care aligns with the growing demand for specialized treatments in Russia, positioning OOO "Jodas Expoim" as a key player in the importation and distribution of these critical therapeutic areas.

OOO "Jodas Expoim" maintains a robust distribution network within Russia, ensuring the efficient delivery of imported pharmaceutical products across the country. While specific warehouse locations are not publicly disclosed, the company is known to collaborate with local partners to build distribution networks across regions such as Latin America, Africa, Asia Pacific, Russia, CIS, and the Middle East. This extensive network enables the company to effectively serve various regions within Russia, meeting the diverse healthcare needs of the population.

The company's logistics capabilities are supported by its partnership with Jodas Expoim Private Limited in India, which operates state-of-the-art manufacturing facilities. These facilities are EU-GMP certified, WHO GMP certified, and PIC/S approved, ensuring the production of high-quality pharmaceutical formulations. This collaboration ensures a steady supply of essential medications to the Russian market, reinforcing OOO "Jodas Expoim"'s role as a key importer and distributor of pharmaceutical products.

OOO "Jodas Expoim" plays a pivotal role in Russia's pharmaceutical supply chain as a primary wholesaler and importer. By sourcing finished pharmaceutical formulations from India, the company ensures the availability of essential medications, particularly in the oncology and critical care sectors. This strategic focus addresses the growing demand for specialized treatments in Russia, positioning OOO "Jodas Expoim" as a key player in the importation and distribution of these critical therapeutic areas.

The company's partnership with Jodas Expoim Private Limited in India facilitates the efficient importation and distribution of high-quality pharmaceutical formulations. This collaboration underscores OOO "Jodas Expoim"'s commitment to providing the Russian healthcare system with access to essential medications, thereby enhancing the overall quality of patient care.

OOO "Jodas Expoim" demonstrates a high level of sourcing concentration, importing 100% of its pharmaceutical products from a single supplier: Jodas Expoim Private Limited in India. This exclusive partnership has resulted in a total import value of $10.6 million USD over 217 shipments, encompassing 20 products across six therapeutic categories. The top five products imported include Paclitaxel ($1.8 million, 0.9% share), Oxaliplatin ($1.4 million, 1.7% share), Imatinib ($1.2 million, 1.4% share), Gemcitabine ($1.1 million, 1.0% share), and Docetaxel ($700,000, 0.8% share).

This sourcing strategy indicates a strategic choice to maintain a streamlined supply chain and ensure consistent product quality. The exclusive relationship with Jodas Expoim Private Limited suggests a stable and reliable partnership, reducing the complexities associated with managing multiple suppliers. However, this concentration also exposes OOO "Jodas Expoim" to potential risks related to supply chain disruptions, such as production delays or regulatory changes affecting the sole supplier.

The resilience of OOO "Jodas Expoim"'s supply chain is closely tied to its exclusive partnership with Jodas Expoim Private Limited in India. This collaboration ensures a consistent supply of high-quality pharmaceutical formulations, supported by Jodas Expoim Private Limited's state-of-the-art manufacturing facilities, which are EU-GMP certified, WHO GMP certified, and PIC/S approved.

While the exclusive sourcing strategy offers stability, it also presents potential vulnerabilities. Any disruptions in Jodas Expoim Private Limited's production capabilities, such as regulatory challenges or operational issues, could impact OOO "Jodas Expoim"'s ability to meet the demand for imported pharmaceutical products in Russia. To mitigate these risks, it would be prudent for OOO "Jodas Expoim" to explore the development of relationships with additional suppliers, thereby diversifying its supply chain and enhancing its resilience against potential disruptions.

The exclusive sourcing pattern of OOO "Jodas Expoim" from Jodas Expoim Private Limited positions the company as a key importer of specialized pharmaceutical formulations in Russia. This strategic focus on oncology and critical care medications aligns with the growing demand for specialized treatments in the Russian healthcare market, potentially enhancing OOO "Jodas Expoim"'s competitive position.

For Indian exporters seeking to become alternative suppliers to OOO "Jodas Expoim," understanding the company's emphasis on high-quality, specialized pharmaceutical formulations is crucial. Demonstrating compliance with international quality standards, such as EU-GMP, WHO GMP, and PIC/S certifications, will be essential in establishing credibility and trust. Additionally, offering a diverse portfolio of products within the oncology and critical care therapeutic areas can provide a competitive edge in meeting OOO "Jodas Expoim"'s specific sourcing needs.

In Russia, the regulation of pharmaceutical imports is governed by the Federal Service for Surveillance in Healthcare (Roszdravnadzor), which operates under the Ministry of Health of the Russian Federation. The primary legislation overseeing the circulation of medicines is the Federal Law No. 61-FZ "On Circulation of Medicines," enacted on April 12, 2010. This law outlines the procedures for the importation, registration, and distribution of pharmaceutical products within Russia.

The marketing authorization pathway for Indian generics involves obtaining a state registration certificate from Roszdravnadzor. This process includes the submission of comprehensive documentation, such as clinical trial data, quality control reports, and evidence of compliance with Good Manufacturing Practices (GMP). The registration ensures that imported pharmaceutical products meet the safety, efficacy, and quality standards required for the Russian market.

Import licensing requirements in Russia stipulate that all pharmaceutical products must be registered with Roszdravnadzor before they can be imported and distributed. This registration process involves the submission of detailed product dossiers, including information on manufacturing processes, quality control measures, and clinical efficacy. Additionally, the manufacturing facilities of the exporting company must hold valid GMP certificates recognized by Roszdravnadzor.

Recognized GMP certificates include those issued by the European Union (EU-GMP), the World Health Organization (WHO GMP), and the Pharmaceutical Inspection Co-operation Scheme (PIC/S). These certifications demonstrate compliance with international quality standards and are essential for the acceptance of pharmaceutical products in the Russian market. Furthermore, wholesale distribution authorization is required for entities involved in the distribution of pharmaceutical products within Russia, ensuring that all intermediaries in the supply chain adhere to regulatory standards.

Imported pharmaceutical products in Russia are subject to batch testing and stability requirements to ensure their safety and efficacy. These tests are conducted by accredited laboratories to verify that the products meet the specified quality standards. Labeling requirements mandate that product labels be in Russian and include essential information such as the product name, dosage form, strength, manufacturing and expiration dates, storage conditions, and instructions for use.

Serialization mandates are also in place to enhance traceability and prevent counterfeit products from entering the market. Each unit of sale must bear a unique serial number, which is recorded in a centralized database accessible to regulatory authorities. This system facilitates the monitoring of product movements throughout the supply chain and ensures that only authorized products reach consumers.

Between 2024 and 2026, Russia implemented several regulatory changes affecting pharmaceutical imports. These changes included the introduction of stricter quality control measures, enhanced requirements for clinical trial data, and the adoption of more rigorous labeling and serialization standards. These measures aim to improve the safety and efficacy of pharmaceutical products available in the Russian market and align with international best practices.

OOO "Jodas Expoim" focuses on importing pharmaceutical products in the oncology and critical care therapeutic areas. This strategic emphasis addresses the growing demand for specialized treatments in Russia, where there is an increasing prevalence of cancer and critical health conditions. By sourcing high-quality generic formulations from India, the company aims to provide affordable and effective treatment options to the Russian healthcare system.

The market demand for these products is driven by the need for